Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment. © 2024. The Author(s).

Citation

Yue Huang, Kangni Zou, Heng Jiang, Zhengyu Li. The complex role of IL-10 in malignant ascites: a review. Cancer immunology, immunotherapy : CII. 2024 Jan 27;73(2):32

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38279997

View Full Text